X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4307) 4307
Publication (545) 545
Book Review (78) 78
Book Chapter (14) 14
Conference Proceeding (3) 3
Government Document (3) 3
Magazine Article (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
docosahexaenoic acid (2897) 2897
index medicus (2658) 2658
humans (2515) 2515
animals (1834) 1834
male (1567) 1567
female (1292) 1292
eicosapentaenoic acid (1276) 1276
omega-3 fatty acids (1191) 1191
fatty acids (1052) 1052
polyunsaturated fatty-acids (969) 969
docosahexaenoic acids - therapeutic use (908) 908
unsaturated fatty acids (906) 906
dietary supplements (889) 889
lipids (795) 795
nutrition & dietetics (757) 757
biochemistry & molecular biology (727) 727
inflammation (716) 716
docosahexaenoic acids - pharmacology (672) 672
fatty acids, omega-3 - therapeutic use (663) 663
mice (624) 624
rats (581) 581
adult (549) 549
middle aged (532) 532
pharmacology & pharmacy (519) 519
fish-oil (515) 515
diet (506) 506
eicosapentaenoic acid - therapeutic use (496) 496
neurosciences (496) 496
oxidative stress (496) 496
docosahexaenoic acids - administration & dosage (467) 467
analysis (445) 445
cell biology (426) 426
article (419) 419
brain (409) 409
aged (397) 397
double-blind method (391) 391
health aspects (389) 389
research (382) 382
docosahexaenoic acids - metabolism (378) 378
supplementation (368) 368
omega-3-fatty-acids (365) 365
fatty acids, omega-3 - administration & dosage (363) 363
polyunsaturated fatty acids (362) 362
physiological aspects (346) 346
disease models, animal (338) 338
fish oils (338) 338
fish oil (323) 323
endocrinology & metabolism (322) 322
arachidonic acid (319) 319
fatty acids, omega-3 - pharmacology (316) 316
fatty-acids (315) 315
treatment outcome (308) 308
nutrition (307) 307
metabolism (299) 299
risk factors (292) 292
double-blind (291) 291
dha (289) 289
rodents (282) 282
fish oils - therapeutic use (281) 281
alpha-linolenic acid (278) 278
apoptosis (278) 278
eicosapentaenoic acid - administration & dosage (263) 263
eicosapentaenoic acid - pharmacology (256) 256
care and treatment (245) 245
cardiovascular-disease (244) 244
medicine (242) 242
prevention (242) 242
docosahexaenoic acids - blood (239) 239
fatty acids, omega-3 - metabolism (236) 236
arachidonic-acid (235) 235
cancer (233) 233
mice, inbred c57bl (220) 220
n-3 fatty-acids (218) 218
brain - metabolism (217) 217
docosahexaenoic acids (217) 217
disease (216) 216
expression (216) 216
omega-3 (216) 216
proteins (214) 214
gene expression (213) 213
risk (212) 212
pregnancy (209) 209
psychiatry (208) 208
dose-response relationship, drug (207) 207
alzheimers-disease (205) 205
rats, sprague-dawley (200) 200
research article (198) 198
cholesterol (193) 193
drug combinations (190) 190
alzheimer's disease (189) 189
cardiovascular disease (187) 187
review (186) 186
coronary-heart-disease (185) 185
antioxidants (182) 182
multidisciplinary sciences (182) 182
studies (180) 180
fish-oil supplementation (176) 176
child (175) 175
rats, wistar (175) 175
neurology (174) 174
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4254) 4254
Japanese (14) 14
Spanish (11) 11
German (9) 9
French (7) 7
Russian (7) 7
Polish (4) 4
Chinese (3) 3
Hungarian (2) 2
Korean (2) 2
Bulgarian (1) 1
Czech (1) 1
Dutch (1) 1
Italian (1) 1
Norwegian (1) 1
Portuguese (1) 1
Romanian (1) 1
Slovak (1) 1
Swedish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
JAMA, ISSN 0098-7484, 10/2011, Volume 306, Issue 14, pp. 1574 - 1581
Journal Article
Journal Article
British Journal of Pharmacology, ISSN 0007-1188, 2013, Volume 169, Issue 4, pp. 772 - 783
N-3 long chain polyunsaturated fatty acids (n-3 LC PUFAs), in particular a-linolenic acid (18:3n-3), eicosapentaenoic acid (EPA; 20:5n-3) and docosahexaenoic... 
in-vivo | n-3 | acylethanolamines | cannabinoid-receptor | cardiovascular-disease | amide hydrolase | rat-brain | cancer cell-lines | anandamide | arachidonoyl-serotonin | PUFA, DHA, EPA | endocannabinoid system | n‐3 | fish oil | Endocannabinoids - metabolism | Ethanolamine - therapeutic use | Neuroprotective Agents - therapeutic use | Cannabinoid Receptor Agonists - metabolism | Polyunsaturated Alkamides - chemistry | Eicosapentaenoic Acid - analogs & derivatives | Humans | Fatty Acids, Omega-3 - chemistry | Polyunsaturated Alkamides - therapeutic use | alpha-Linolenic Acid - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - chemistry | Cannabinoid Receptor Agonists - chemistry | Neuroprotective Agents - metabolism | Drug Delivery Systems | Receptors, Cannabinoid - metabolism | Ethanolamine - chemistry | Cannabinoid Receptor Agonists - therapeutic use | Fishes | Anti-Inflammatory Agents, Non-Steroidal - metabolism | Dopamine - metabolism | Endocannabinoids - therapeutic use | Receptors, Cannabinoid - chemistry | Acylation | Docosahexaenoic Acids - therapeutic use | Dopamine - therapeutic use | Fatty Acids, Omega-3 - metabolism | Neuroprotective Agents - chemistry | alpha-Linolenic Acid - analogs & derivatives | Ethanolamine - metabolism | Eicosapentaenoic Acid - metabolism | Polyunsaturated Alkamides - metabolism | Docosahexaenoic Acids - analogs & derivatives | Animals | Dopamine - analogs & derivatives | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | alpha-Linolenic Acid - metabolism | Fatty Acids, Omega-3 - therapeutic use | Eicosapentaenoic Acid - therapeutic use | Seafood - analysis | Dietary Supplements | Fish Oils - chemistry | Endocannabinoids - chemistry | Docosahexaenoic Acids - metabolism | Ethanolamines | Omega-3 fatty acids | Linolenic acids | Fatty acids | Dopamine | Cannabinoids 2012, Part Two | Themed Section
Journal Article
British Journal of Nutrition, ISSN 0007-1145, 3/2012, Volume 107, Issue 11, pp. 1 - 12
Depressive symptoms may increase the risk of progressing from mild cognitive impairment (MCI) to dementia. Consumption of n-3 PUFA may alleviate both cognitive... 
Depression | DHA | Mild cognitive impairment | n-3 Fatty acids | EPA | Dementia | ALZHEIMERS-DISEASE | OMEGA-3-FATTY-ACIDS | MAJOR DEPRESSION | SUPPLEMENTATION | NUTRITION & DIETETICS | DOCOSAHEXAENOIC ACID | DOUBLE-BLIND | FISH-OIL | PLACEBO-CONTROLLED TRIAL | HEALTH | Depression - physiopathology | Cognition Disorders - blood | Humans | Male | Patient Dropouts | Dietary Supplements - analysis | Fatty Acids, Omega-3 - analysis | Fish Oils - therapeutic use | Psychiatric Status Rating Scales | Speech Disorders - etiology | Aged, 80 and over | Female | Executive Function | Cognition Disorders - psychology | Docosahexaenoic Acids - therapeutic use | Severity of Illness Index | Cognition Disorders - physiopathology | Fatty Acids, Omega-3 - metabolism | Eicosapentaenoic Acid - metabolism | Docosahexaenoic Acids - analysis | Memory Disorders - prevention & control | Memory Disorders - etiology | Depression - diet therapy | Erythrocytes - metabolism | Depression - psychology | Fatty Acids, Omega-3 - therapeutic use | Fish Oils - metabolism | Quality of Life | Aged | Eicosapentaenoic Acid - therapeutic use | Australia | Eicosapentaenoic Acid - analysis | Fish Oils - chemistry | Speech Disorders - prevention & control | Cognition Disorders - diet therapy | Depression - blood | Docosahexaenoic Acids - metabolism | Older people | Memory | Dietary supplements | Cognitive ability | Clinical trials | Mental depression | Fatty acids | Quality of life
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2009, Volume 54, Issue 7, pp. 585 - 594
Omega-3 polyunsaturated fatty acid (ω-3 PUFA) therapy continues to show great promise in primary and, particularly in secondary prevention of cardiovascular... 
Cardiovascular | Internal Medicine | ω-3 polyunsaturated fatty acids | fish oils | cardiovascular diseases | CARDIAC & CARDIOVASCULAR SYSTEMS | RATE-VARIABILITY | MYOCARDIAL-INFARCTION | omega-3 polyunsaturated fatty acids | ATRIAL-FIBRILLATION | PLASMA-LIPIDS | DOCOSAHEXAENOIC ACID | ADIPONECTIN SECRETION | FISH-OIL | CORONARY-HEART-DISEASE | EICOSAPENTAENOIC ACID | ALPHA-LINOLENIC ACID | Prognosis | Cardiovascular Diseases - prevention & control | Humans | Eicosapentaenoic Acid - administration & dosage | Secondary Prevention | Heart Failure - prevention & control | Fishes | Cardiovascular Diseases - mortality | Fish Oils - administration & dosage | Fatty Acids, Omega-3 - administration & dosage | Heart Failure - mortality | Cardiomyopathies - drug therapy | Docosahexaenoic Acids - therapeutic use | Cardiovascular Diseases - physiopathology | Atherosclerosis - drug therapy | Heart Conduction System - drug effects | Docosahexaenoic Acids - administration & dosage | Randomized Controlled Trials as Topic | Arrhythmias, Cardiac - drug therapy | Coronary Disease - prevention & control | Animals | Diet | Heart Conduction System - physiopathology | Fatty Acids, Omega-3 - therapeutic use | Eicosapentaenoic Acid - therapeutic use | Seafood - analysis | Heart failure | Prosthesis | Implants, Artificial | Cardiac patients | Low density lipoproteins | Atrial fibrillation | Linolenic acids | Omega-3 fatty acids | Heart attack | Prevention | Medical colleges | Unsaturated fatty acids | Studies | Vegetable oils | Heart attacks | Fish oils | Mortality | Oils & fats | Fatty acids
Journal Article